8 May 2026 in Nature Genetics
Rare-variant association studies typically perform gene-level tests in which coding variants are filtered (or ‘masked’) and aggregated based on functional annotation and allele frequency. Through a systematic literature review, we cataloged 664 masks used across 234 studies and found that masking strategies (that is, sets of masks) rarely repeat across studies and are rarely justified. To quantify their impact on association results, we applied all previously employed strategies to 54 traits within 189,947 UK Biobank exomes. Here we find that the number of significant associations greatly depends on the masking strategy (ranging from 58 to 2,523 associations), which is a key reason for the modest overlap (<30%) of associations between separate published analyses of this dataset. We empirically determine masking strategies with high discovery power for low-frequency and rare variant gene-level associations across numerous datasets and traits, and we use these to explore the impact of other factors on burden test results. These findings offer a baseline strategy in burden tests to increase study power and replicability, addressing one source of inconsistency in previous studies.
5 May 2026 in Nature Communications
Polygenic scores can improve atrial fibrillation risk prediction. However, limited accuracy and cross-ancestry transferability hinder clinical translation. Here, we explore several ensemble approaches to generate ancestry-optimized polygenic scores, with development in diverse participants from the All of Us Research Program, BioBank Japan, and three additional cohorts. Our ancestry-specific multi-trait approach particularly improves prediction in South-Asian (odds-ratio/standard deviation 1.5–1.8; area under curve 0.60-0.64; relative R² +71%), Admixed-American (1.5; 0.60; +34%) and African ancestry groups (1.4; 0.57; +56%). Nevertheless, performance remains highest in European and East-Asian ancestries (1.8–2.2; 0.65–0.68), where >50% of SNP-heritability is explained. Improved risk stratification is also observed at the extremes, identifying European and East-Asian ancestry individuals with risk comparable to rare TTN variants (e.g., 6–11% with >4-fold odds). Finally, our scores improve incident risk prediction alongside clinical models. Together, we show that our ancestry-tailored multi-trait polygenic scores advance atrial fibrillation risk prediction and stratification, providing an equitable foundation for implementation.
3 October 2025 in Research Square
Polygenic scores (PGSs) can improve atrial fibrillation (AF) risk prediction, both alone and alongside clinical scores, offering potential for guiding targeted screening. However, their limited accuracy and cross-ancestry transferability remain major barriers to clinical translation. Here, we explored several multi-PGS approaches to generate ancestry-optimized PGSs for AF, and tested these in independent samples from the All of Us Research Program. Our ancestry-specific multi-trait approach, which leverages correlated traits, in particular outperformed the current gold-standard PGS among Asian (OR/SD = 1.76 [1.56–1.99]; AUROC = 0.637; AUPRC = 0.055), Admixed American (1.45 [1.38–1.53]; 0.595; 0.054) and African ancestry groups (1.39 [1.32–1.45]; 0.573; 0.064). Although predictive accuracy remained highest among Europeans (1.89 [1.85–1.93]; 0.646; 0.157) - in whom our PGS explained ~ 50% of SNP-heritability - our multi-trait approach yielded relatively larger gains in non-European populations. Improved risk stratification was also observed at PGS extremes, identifying a substantial proportion of European individuals with risk comparable to rare TTN variants (e.g., 5.8% with > 4-fold odds). Overall, our ancestry-tailored multi-trait PGSs advance equitable AF risk prediction and provide a foundation for implementation.
27 January 2026 in Research Square
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are heart muscle diseases with largely opposing structural and functional phenotypes. Yet, both may lead to the same devastating outcomes of advanced heart failure and life-threatening arrhythmias. Using genome-wide association data from 9,365 DCM cases, 5,900 HCM cases, and over 1.2 million controls, we show that DCM and HCM are largely inversely associated across multiple genomic levels. Modeling both disorders as opposing genetic entities, in case-case GWAS approaches, we identify 100 loci (17 novel) underlying the cardiomyopathy spectrum. Several loci map to potential therapeutic targets (e.g., ADM , CACNA2D2 ), and polygenic risk scores derived from these data show strong discrimination between DCM and HCM patients in external datasets (AUC 0.78-0.84; AUPRC ~ 0.85). The pervasive opposing associations suggest that cardiomyocyte-directed therapies may often have opposite effects in DCM versus HCM. Nevertheless, a shared-effect analysis reveals a single locus — near the calcium-buffering gene CASQ2 — and also identifies a concordant genomic component associated with cardiometabolic health and extracardiac risk factors. By leveraging the shared and opposing genetic mechanisms of DCM and HCM, our work defines the genomic architecture of major cardiomyopathy subtypes and suggests new directions for therapeutics and precision medicine in heart failure.